| Product Unit Size | Cost | Quantity | Stock |
|---|
BAY-1816032 is an inhibitor of budding uninhibited by benzimidazoles 1 kinase (BUB1). When used alone or in combination with taxanes, ATR, and PARP inhibitors, BAY-1816032 inhibits tumor growth in human triple-negative breast xenograft models in vivo to varying degrees. Treatment with BAY-1816032 in combination with both paclitaxel or olaparib resulted in a further reduction in tumor size compared to the monotherapies.
| Cas No. | 1891087-61-8 |
|---|---|
| Purity | ≥99% |
| Formula | C27H24F2N6O4 |
| Formula Wt. | 534.52 |
| IUPAC Name | 2-[3,5-difluoro-4-[[3-[5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl]indazol-1-yl]methyl]phenoxy]ethanol |
| Synonym | BAY 1816032, BAY1816032 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Siemeister G., Mengel A., Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo. Clin Cancer Res. 25(4):1404-1414 (2019). PMID:30429199.